We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gear Up for Globus Medical (GMED) Q3 Earnings: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
The upcoming report from Globus Medical (GMED - Free Report) is expected to reveal quarterly earnings of $0.65 per share, indicating an increase of 14% compared to the year-ago period. Analysts forecast revenues of $604.93 million, representing an increase of 57.7% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Globus Medical metrics that are commonly tracked and forecasted by Wall Street analysts.
The combined assessment of analysts suggests that 'Net Sales by Product Category- Enabling Technologies' will likely reach $31.12 million. The estimate indicates a change of +12.5% from the prior-year quarter.
Analysts predict that the 'Net Sales by Product Category- Musculoskeletal Solutions' will reach $572.79 million. The estimate points to a change of +64.9% from the year-ago quarter.
According to the collective judgment of analysts, 'Geographic Revenues- International' should come in at $117.63 million. The estimate indicates a change of +58.4% from the prior-year quarter.
Analysts forecast 'Geographic Revenues- United States' to reach $483.82 million. The estimate suggests a change of +56.4% year over year.
Over the past month, Globus Medical shares have recorded returns of +7.3% versus the Zacks S&P 500 composite's +1% change. Based on its Zacks Rank #2 (Buy), GMED will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gear Up for Globus Medical (GMED) Q3 Earnings: Wall Street Estimates for Key Metrics
The upcoming report from Globus Medical (GMED - Free Report) is expected to reveal quarterly earnings of $0.65 per share, indicating an increase of 14% compared to the year-ago period. Analysts forecast revenues of $604.93 million, representing an increase of 57.7% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Globus Medical metrics that are commonly tracked and forecasted by Wall Street analysts.
The combined assessment of analysts suggests that 'Net Sales by Product Category- Enabling Technologies' will likely reach $31.12 million. The estimate indicates a change of +12.5% from the prior-year quarter.
Analysts predict that the 'Net Sales by Product Category- Musculoskeletal Solutions' will reach $572.79 million. The estimate points to a change of +64.9% from the year-ago quarter.
According to the collective judgment of analysts, 'Geographic Revenues- International' should come in at $117.63 million. The estimate indicates a change of +58.4% from the prior-year quarter.
Analysts forecast 'Geographic Revenues- United States' to reach $483.82 million. The estimate suggests a change of +56.4% year over year.
View all Key Company Metrics for Globus Medical here>>>
Over the past month, Globus Medical shares have recorded returns of +7.3% versus the Zacks S&P 500 composite's +1% change. Based on its Zacks Rank #2 (Buy), GMED will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>